Entities / Company
Ocugen.
biopharmaceutical company
- Reports this week
- 0
- Active events
- 0
- Connections
- 19
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Earlier this month
Gone quiet
No new reports in 90+ days-
Ocugen addressed unmet medical needs for Stargardt patients through recent announcements regarding their research in Europe.Some support1 report2 developments inside
-
Huma Qamar was appointed Chief Medical Officer at Ocugen.Some support2 reports
-
Ocugen is updating its Retina Scientific Advisory Board, while Peter K Kaiser holds chairs at Cleveland Clinic and Ophthalmic Consultants of Boston.Some support1 report
-
Ocugen announced a regional partnership for OCU400 in Korea.Some support1 report1 development inside
-
Ocugen secured exclusive Korean rights for OCU400, and FDA concurrence was granted, enabling BLA submission.Some support1 report
-
Ocugen filed a registration statement with the Securities and Exchange Commission on August 13, 2025.Some support1 report
-
Ocugen announced it will participate in the Biotech on Tap 2025 conference.Some support2 reports
No events began in the chosen period. Widen it, or reset.
Around Ocugen this week
News at the entities that move Ocugen most-
FDA StructuralGeneric medicine services are seeking approval for launch from the FDA.Moves Ocugen
-
Korea OperationalJamaica and Korea competed in the WorldSkills Competition.Moves Ocugen
Connections
The 4 strongest of 19, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
FDA Structural
Ocugen's clinical development and ability to conduct trials are fundamentally dependent on regulatory approvals and designations granted by the FDA.
-
Huma Qamar Structural
Huma Qamar serves as the Chief Medical Officer at Ocugen.
-
Korea Operational
Ocugen is actively operating in the Korean market, securing exclusive rights and forming regional partnerships for its gene therapy.
-
Alena Kohušová Shared context
Both entities are mentioned within the context of the European Medicines Agency regulatory environment.
History
Events by the month they beganSeptember 2026
1 eventJune 2026
7 events- Ocugen addressed unmet medical needs for Stargardt patients through recent announcements regarding their research in Europe.
- Huma Qamar was appointed Chief Medical Officer at Ocugen.
- Ocugen is updating its Retina Scientific Advisory Board, while Peter K Kaiser holds chairs at Cleveland Clinic and Ophthalmic Consultants of Boston.
- Ocugen announced a regional partnership for OCU400 in Korea.
- Ocugen secured exclusive Korean rights for OCU400, and FDA concurrence was granted, enabling BLA submission.
- Ocugen filed a registration statement with the Securities and Exchange Commission on August 13, 2025.
- Ocugen announced it will participate in the Biotech on Tap 2025 conference.